Parkinson's

Maligned peptides such as the Alzheimer’s-associated amyloid precursor protein may have critical roles in the healthy brain.

The normal functions of peptides that aggregate in Alzheimer’s, Parkinson’s, and Huntington’s have been largely overlooked by scientists, but some argue that they are critical for understanding the development of disease.

Testing in animals and lab-grown cells suggests the experimental drug could enhance the function of lysosomes within cells.

A study shows “sonogenetics” could be a useful new tool in neuroscience and other fields.

The University of Toronto and University of Vienna pharmacologist developed L-dopa, a precursor to dopamine that remains the most widely used therapy for Parkinson’s disease.

The plant geneticist has revolutionized researchers’ understanding of how light affects plant growth and development, and is engineering plants to combat climate change.

Several early-stage clinical trials indicate that implanting patients with the cells is safe. But whether they can alleviate neurological problems remains to be seen.

New evidence points to a waste-clearing problem in patients’ cells, rather than the accumulation of protein tangles, as the root cause of the neurodegenerative disease.

Damage to the lysosome, the organelle that removes excess proteins, lipids, and other materials, might be at the root of the disease.

Johns Hopkins’s Ted Dawson discusses his lab’s demonstration that misfolded α-synuclein can move from the stomach to the brain and cause physical and cognitive symptoms.

Researchers teamed up with a woman with a keen sense of smell to identify telling differences between healthy people and those with the neurodegenerative disease.

Since their discovery in 2006, induced pluripotent stem cells have been poised to reprogram regenerative medicine. Twelve years on, here’s how far they’ve come.

The founding editor-in-chief will redirect his focus to a Parkinson’s organization.

Surgeons will inject approximately 5 million dopamine-producing progenitor cells into patients’ brains.

Researchers initially set out to investigate the relationship between copper homeostasis and the rare Menkes disease, but they also found links to Parkinson’s.

The $340 million, 30,000-square-foot center will produce cells for therapeutic applications.